11 Jun AQUAPORIN A/S ENTERS AGREEMENT FOR RO MEMBRANE DEVELOPMENT, SUPPLY AND DISTRIBUTION

Aquaporin > News > News > AQUAPORIN A/S ENTERS AGREEMENT FOR RO MEMBRANE DEVELOPMENT, SUPPLY AND DISTRIBUTION

AQUAPORIN ENTERS NEW AGREEMENT FOR RO MEMBRANE DEVELOPMENT

As of June 2018, Aquaporin A/S has entered a Development, Supply and Distribution agreement for Aquaporin Inside® RO (reverse osmosis) membranes, with a major global systems integrator and solution provider in a specific industry.

This agreement with both development and commercial activities represents an important step in the commercialization of the Aquaporin Inside® Technology and supports the Aquaporin A/S strategy of going to market with leading system suppliers in select markets.

“Aquaporin A/S launched its first product in 2017 and is continuing to bring products to market. We are happy to have entered an important development and commercialization agreement in this process. We have the right company in the specific industry and look forward to a strong business relationship going forward”, says Peter Holme Jensen, CEO Aquaporin A/S.

Further information:

COO of AquaporinThomas Christian Beck – website: www.aquaporin.com – phone: +45 27 10 20 51 – tcb@aquaporin.com

Aquaporin A/S is a water technology company headquartered in Copenhagen, Denmark with activities in Singapore and China. Our company is dedicated to revolutionizing water purification through the use of industrial biotechnological techniques and thinking. Our company is a global leader in developing, producing and marketing biomimetic membranes for industrial and consumer water applications based on nature’s own water filtration system – the highly selective and efficient aquaporin water channels, capable of separating and purifying water from all other compounds. The Aquaporin Inside® platform uses biotechnological principles in a technological context – an emerging field with immense commercial perspectives. For more information, visit www.aquaporin.com



SIGN UP FOR OUR NEWSLETTER

Invalid email.
Get your newsletter about: